Abstract
In the recent years, integrase (IN) has emerged as an important new target for the development of anti-HIV-1 agents. The enzyme is involved in a key stage of the retroviral replicative cycle, and interacts with a range of cellular co-factors. Due to the absolute necessity of the enzyme for successful infection and the range of cellular cofactors employed by the enzyme, new ways of targeting both IN and its cofactors could yield agents with improved resistance profiles. Allosteric inhibitors are currently receiving a great deal of focus from both academia and industry alike and offer the possibility of a new class of anti-HIV-1 inhibitor.
Keywords: ALLINI, Allosteric, HIV-1, Integrase, LEDGIN, LEDGF/p75, Multimerization, PIC, Retrovirus, STI.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Recent Advances in Anti-Infective Drug Discovery
Recent Patents on Anti-Infective Drug Discovery
Current Metabolomics and Systems Biology (Discontinued)
Recent Advances in Inflammation & Allergy Drug Discovery
Current HIV Research
Anti-Infective Agents
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents